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Abstract
This review describes the use of polymer micelle nanotechnology based chemotherapies for ovarian cancer. While
various chemotherapeutic agents can be utilized to improve the survival rate of patients with ovarian cancer, their
distribution throughout the entire body results in high normal organ toxicity. Polymer micelle nanotechnology
aims to improve the therapeutic efficacy of anti-cancer drugs while minimizing the side effects. Herein, different
types of polymer micelle technology based nanotherapies such as PLGA, polymerosomes, acid cleavable, thermo-
sensitive, pH sensitive, and cross-linked micelles are introduced and structural differences are explained. Addition-
ally, production methods, stability, sustainability, drug incorporation and drug release profiles of various polymer
micelle based nanoformulations are discussed. An important feature of polymer micelle nanotechnology is the
small size (10-100 nm) of particles which improves circulation and enables superior accumulation of the therapeu-
tic drugs at the tumor sites. This review provides a comprehensive evaluation of different types of polymer micelles
and their implications in ovarian cancer therapeutics.
Introduction
Ovarian cancer is the fifth most prevalent cancer among
women with a life time risk of 1.4 to 1.8% for women
living in the US. There are no early symptoms for ovar-
ian cancer which hinders detection until it reaches
advanced stages. Survival of the patients is primarily
dependent on the disease stage of the patients. For
example, stage I, II, III, and IV ovarian cancer have
median 5-year survival rates of approximately 93%, 70%,
37%, and 25%, respectively [1,2]. Diagnosed ovarian can-
cers can be treated by eliminating the cancerous tissue
through surgery and care must be taken to prevent the
disease from recurring. Surgery alone is effective for
only stage I disease, whereas chemotherapy is required
in all other stages of ovarian cancer [3]. Therefore, our
current review article is focused on the concept of
improving the efficacy of ovarian cancer therapeutics
using polymer micelle nanotechnology approaches.
Chemotherapy Agents used for Ovarian Cancer Treatment
Chemotherapy helps to improve the overall survival of
patients with ovarian cancer. Many chemotherapeutic
agents (anti-cancer drugs) are available, including cispla-
tin (CP), paclitaxel (PTX), doxorubicin (DOX), decita-
bine (DB), gemcitabine, and their combinations for
ovarian cancer treatment. There is significant interest in
identifying novel therapeutic agents and improving the
efficacy of existing therapeutic modalities. A number of
randomized trials treating advanced ovarian cancer
using a combination chemotherapy with HEXA-CAF
(hexamethyl melamine (HMMA), cyclophosphamide
(CPP), methotrexate (MTX) and fluorouracil (FU)) have
achieved higher survival rates than using a single thera-
peutic agent [4]. Other clinical studies using cisplatin,
adriamycin, and cyclophosphamide were initiated for
stage III and IV ovarian cancer [5-8]. Nevertheless,
these trials have not shown a significant benefit of one
type of chemotherapy over another. Cisplatin and carbo-
platin (CBP) have been the most effective chemothera-
peutic regimens for more than two decades [9,10]. The
majority of current treatment approaches use platinum-
containing compounds such as cisplatin, oxaliplatin and
transplatin [11-14]. Additionally, paclitaxel (Taxol, TAX)
has been recognized as the most efficient chemothera-
peutic agent for relapsed ovarian cancer [15]. Doxorubi-
cin, in the form of doxorubicin HCl liposome injection
(Doxil or Adiramycin®), has also been considered to be
an effective therapeutic agent for many years [16].
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A combination of doxorubicin, cyclophosphamide, and
cisplatin resulted in an increase of 6% in the survival
rate of patients versus a treatment of only cyclopho-
sphamide or cisplatin [17]. Gemcitabine has shown posi-
tive response in patients who are resistant to cisplatin
therapy and it is also a well tolerated drug [18]. An
overall 74% response rate was achieved using a combi-
nation of gemcitabine with platinum (Gemplat or Gem-
Cis) for recurrent carcinoma [19-22]. A flow chart
outlining the management of chemotherapeutic strate-
gies is provided in the Figure 1.
It is evident from Figure 1 that, most of the che-
motherapeutic drugs have demonstrated a significant
therapeutic outcome, at the same time they exhibited
adverse side effects [23]. Further, they are not effective
in treating the recurrence of ovarian cancer. Impor-
tantly, ovarian cancer patients are often initially respon-
sive to these therapeutic modalities but eventually
become resistant to therapy. Therefore, drug resistance
remains the major obstacle in ovarian cancer treatment.
One way to improve the efficacy and specificity of che-
motherapeutic agents is through nanotechnology based
formulations (encapsulated, conjugated, or entrapped/
loaded forms in nanocarriers or drug delivery vehicle/
vectors). Nanotechnology mediated therapies promote a
controlled delivery of chemotherapeutic drug(s) in a tar-
geted way which directly acts on the cancer site for pro-
longed periods of time with minimal or no normal
organ toxicity. Therefore, this review will focus on the
design of nanotechnology formulations for ovarian can-
cers treatment.
Nanotechnology in Drug Delivery
Chemotherapeutic agents in solution or polymer solu-
tion which are delivered orally or intravenously have
poor pharmacokinetics with a narrow therapeutic win-
dow (Figure 2A). These agents reach a maximum toler-
ated concentration immediately and then are eliminated
from the blood. An ideal drug formulation with maxi-
mum benefits for patients should release at a minimum
effective concentration over a period of time. Nanotech-
nology promises to play an important role in satisfying
these aspects as a drug delivery carrier/vector (Figure
2B). Nanotechnology based drug carriers such as
Figure 1 Long term treatment strategy for ovarian cancer using various anti-cancer drug combinations.
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polymer-drug conjugates, dendrimer, polymer micelles,
carbon nanotubes, lipid/solid nanoparticles, and polymer
nanoparticles have numerous benefits over conventional
methods. Nanotechnology based therapeutics have been
proven to improve drug efficacy, reduce toxicity in
healthy tissue, and improve patient compliance. Many of
these nanoparticles are currently in use for cancer thera-
pies [24]. A list of clinical and preclinical trials of these
nanotechnology based formulations have been reviewed
by Quan et al. [25]. The design of a universal nanotech-
nology formulation with chemotherapeutic agents is
extremely crucial. A successful formulation, one that
acts as a good therapeutic carrier for the cancer thera-
pies, would exhibit the following features: (a) stable in
the physiological environment, (b) longer circulation life
time (c) avoid opsonization and reticuloendothelial sys-
tem (RES) process, (d) promote endocytosis, and (e)
enhance tumor uptake. The specificity of these formula-
tions can be further enhanced by the conjugation of
antibodies to the nanoformulations and these immuno-
conjugated formulations will have a better therapeutic
efficacy over other drug formulations (Figure 2C).
Drug Delivery Approach
Chemotherapeutic agent(s) or anti-cancer drug(s) delivery
to tumors can be achieved by either a passive or an active
mechanism. These mechanisms are shown in a pictorial
representation in Figure 3. The passive targeting takes
place through the diffusion into tumors or angiogenic
tumor vasculatures which have leaky vessels with smaller
gaps of 100 - 2000 nm. The nanoformulations (drug
loaded nanoparticles) have more interstitial access to the
tumor and enhance the retention in tumors. The leaky
vasculature promotes the uptake of nanoformulations by
the tumors, which become entrapped inside, and due to
impaired and poor lymphatic drainage, promotes
Enhanced Permeation and Retention (EPR) index. In
addition, the size and charge of nanoparticles dictates the
passive targeting to the tumors [25-28]. In comparison,
the active targeting mode utilizes the conjugation of
nanoparticles to immunogens (antibodies or targeting
moieties). Delivery of drugs can be improved through
tumor specific antibody conjugated nanoparticle system
(active targeting) over simple drug loaded nanoparticle
system (passive targeting). First, the transport of nanopar-
ticles uptake by the tumor site is increased by longer cir-
culation as a result of the EPR effect. Secondly, the
targeting moiety assists in endocytosis of nanoparticles
which, in general, increases internalization of nanoparti-
cles for an improved therapeutic effect [29,30]. This tar-
geting approach is promising which has shown enhanced
therapeutic effects in animal models via substantial
Figure 2 Improved and sustained therapuetic effect of chemotherapuetic agents using nanotechnology. (A) Oral or intravenous route
delivery of conventional formulations and nanocarriers. (B) Pictorial structures of various drug delivery devices such as polymer-drug conjugates,
dendrimer, polymer micelle, polymer nanoparticles, and lipid nanoparticles/capsules. (C) Immunoconjugate nanosystems route for improved
therapeutic efficacy.
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increase in nanoparticles internalization in cancer cells
[31,32]. In addition to anti-cancer drug delivery, the
internalization of nanoparticles is also an important factor
in gene, siRNA, DNA and biomacromolecular delivery.
Therefore, combination of controlled and targeted deliv-
ery improves the efficacy of delivering drugs, genes and
biomolecules. In this review we focused on current nano-
formulations, especially on polymer micelle nanosystems
which have been recognized for their special
characteristics.
Polymer Micelle Nanotechnology
Polymer micelle nanotechnology based delivery of che-
motherapeutic agents, imaging agents, biomacromole-
cules and radionuclides in a tumor-targeted way may
enhance diagnosis as well as the outcome of cancer
therapy [33]. In this direction, a few clinical trials of var-
ious polymer micelle nanotechnology therapies are in
the development stage [34]. To describe simply, polymer
micelles are formed by a hydrophobic core layered with
hydrophilic chains through a spontaneous self-assembly
of block or graft copolymers [35,36]. The primary
function of polymer micelles is to protect and improve
the solubility and stability of hydrophobic (lipophilic)
drugs. It has been shown that the aqueous solubility
can be increased up to 30,000-fold [37,38]. In our
studies, we have demonstrated that b-cyclodextrin, poly
(b-cyclodextrin), and polymer nanoparticle curcumin
assemblies can improve stability of curcumin by 6-8 fold
[39-41]. This higher stability occurs when the drug
molecules partition into the hydrophobic core of the
polymer micelles and a protective hydrophilic shell
interface acts as external medium.
There are a number of hydrophobic core-forming bio-
compatible and biodegradable polymer micelles, such as,
poly(ethylene-co-propylene-co-ethylene oxide) (PEO-
b-PPO-b-PPO) or poly(ethylene-co-propylene oxide)
(PEO-b-PPO), poly(lactic acid) (PLA), poly(D,L-lactide)
(PDLLA), poly(lactic-co-glycolic acid) (PLGA), poly(ε-
caprolactone) (PCL), poly(hydroxybutyrate) (PHB), and
poly(beta-benzyl L-asparate) [42-47] being used in drug
delivery applications. The formation of micelles of these
polymers is feasible only at a specific concentration (i.e.,
critical micelle concentration, CMC). The polymer
micelle with a lower CMC value is a better choice for
these applications. Figure 4 schematically presents dif-
ferent models of formation of polymer micelles based
on their self-assembly mechanisms.
Conventional Polymer Micelles
A number of natural or synthetic di-block or tri-block
copolymers which are biodegradable/biocompatible in
nature, have been utilized to load various drugs/biologi-
cal molecules. Among them, poly(lactic-co-glycolic acid)
(PLGA) generated micelles are well known. In addition,
the parent PLGA polymer is FDA approved for use in
industry and medicine. Structurally varied nanoformula-
tions, such as comb-like amphiphilic PLGA-b-poly(ethy-
lene glycol) methacrylate (PLGA-b-PEGMA) copolymer,
PLGA-b-poly(ethylene glycol)-b-PLGA (PLGA-b-PEG-
b-PLGA) tri-block copolymer, three-arm and four-arm
star-shaped PLGA-b-PEG block copolymer micelles are
available for drug delivery applications [48-50]. In addi-
tion, Park et al. [51] recently developed a surface cross-
linking PLGA-b-PEG copolymer to improve the overall
stability of polymer micelles utilizing a shell layer of
vinyl pyrrolidone. A natural carbohydrate polymer (i.e.
hyaluronic acid (HA) copolymer) can be utilized as tar-
get specific micelle carriers for doxorubicin (DOX) by
conjugating to PLGA polymer [52]. This formulation
allowed loading of 4.8-7.2 wt.% DOX (i.e., DOX-HA-g-
PLGA) which exhibited 5.2-fold greater cytotoxicity in
the cancer cells over free DOX (IC50 value of DOX-HA-
g-PLGA = 0.67 mg.mL-1 and free DOX = 3.48 mg.mL-1).
Similarly, a mixed micelle nanoformulation of DOX
Figure 3 A schematic representation of the strategy to target
cancer cells using nanoparticles and immunoconjugated
nanoparticles. Passive targeting occurs through drug loaded
nanoparticles and active targeting is achieved with antibody
conjugated nanoparticles.
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loaded TPGS/PLGA-b-PEG-b-FOL (TPGS = a-
tocopheryl succinate esterified to polyethylene glycol
1000 and FOL = folate) has shown higher cellular
uptake of DOX, which resulted a higher degree of apop-
tosis in drug-resistant cancer cells. Nanoformulation of
PLGA coated with poly(L-lysine)-PEG-folate conjugates
has shown an enhanced cellular uptake via folate recep-
tor-mediated intracellular delivery [53]. Our data also
suggest that PLGA formulations combined with poly
(vinyl alcohol) (PVA) achieved intracellular uptake and
exhibited improved therapeutic effects of curcumin in
cisplatin resistant ovarian (A2780CP) and metastatic
breast (MDA-MB-231) cancer cells (Figure 5) [41].
Other Type of Polymer Micelle Nanoparticles
All drug delivery carrier properties are determined by
their stability, solubility, surface charge and type of func-
tional groups which facilitate the encapsulated drug
release and targeting characteristics to tumor cells.
Pluronic polymers (i.e., poly(ethylene oxide)-b-poly(pro-
pylene oxide)-b-poly(ethylene oxide or PEO-b-PPO-b-
PEO) are known as easily forming micelle drug carriers
with a 40 nm diameter. These micelle nanocarriers have
the ability to increase the solubility of various hydropho-
bic anti-cancer drugs as well as enable passive targeting
to the solid tumor. Studies have also demonstrated that
pluronic micelles promote enhanced cytotoxic activities
of various anti-cancer drugs by sensitization of cancer
cells attributed to the inhibition of P-glycoprotein (P-gp)
activity by depletion of adenosine-5’-triphosphate (ATP)
[54]. Poly(ethylene oxide)-linked poly(ethylene imine)
(PEO-l-PEI) micelle gel is a good example which binds
oligonucleotide (ODN) molecules and its delivery is
enhanced through receptor-mediated delivery. In gen-
eral, ODNs are useful therapeutic agents which suffer
from severe enzymatic degradation by nucleases. Encap-
sulation of ODNs in PEG/PEI micelles not only regu-
lated the growth of ovarian cancer cells (A2780) but
also lowered ODN concentrations and resulted in signif-
icant tumor growth suppression in vivo [54,55]. Simi-
larly, stable micelle formulations of 5’-triphosphates of
cytarabine (araCTP), gemcitabine (dFdCTP), and floxuri-
dine (FdUTP) in PEG-l-PEI networks have been proven
to accumulate faster and inhibit tumor growth in vivo
[56]. Curcumin-casein micelle complexes not only
exhibited higher cytotoxicity against HeLa cells but were
also capable of damaging cell nucleus as a result of
apoptosis at a concentration of 30 μM curcumin [57].
These complexes were also more efficiently internalized
in the cells. In our recent investigations [39,40], we
have proven that the natural anti-cancer and cancer pre-
vention agent, curcumin, is effective in therapies with
self-assembly or nano self-assembly formulations of
b-cyclodextrin or poly(b-cyclodextrin).
PEG/PDLLA-Taxol combination (Genexol®-PM) is a
formulation with high anti-tumor efficacy in human
ovarian cancer cell line (OVCAR-3) [58]. In another
report, triptolide (TP) loaded PDLLA/PEG nanocarrier
was shown to significantly inhibit tumor growth via i.v.
injections at the dose levels of 0.0375, 0.075 and 0.15
mg/kg, and their inhibition rates were 42.5%, 46.0% and
49.9%, respectively. Hydrolyzable polyesters of PCL and
PDLLA are useful formulations to encapsulate paclitaxel,
ellipticine, and doxorubicin drugs [59-61]. Further, a
novel poly(ethyl ethylene phosphate) (PPE, polypho-
sphorus ether) and PCL biodegradable triblock copoly-
mer micelles were developed as drug carriers [62].
These micelles are biodegradable, cytocompatible, small
sized particles and show improved drug loading effi-
ciency with an increase of PPE molecular weight. The
advanced features of these micelles result in more flex-
ibility and their physico-chemical properties can be
adjusted through changing the side group conjugation
to phosphorus [63]. Another biocompatible micelle
(i.e., poly[2-(methacryloyloxy)ethyl phosphorylcholine]
or MPC) conjugated with folate targeting moiety to poly
Figure 4 Different types of polymer micelle formations through the self-assembly process. This process is always favored by hydrophobic-
hydrophobic interactions within the block copolymers. The core is completely hydrophobic which can be used to load anti-cancer drugs.
Reactive functional groups can be utilized for antibody conjugations. Illustrations are based on their chemical structures.
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[2-(diisopropylamino)ethyl methacrylate] (DPA) (i.e.,
MPC-DPA-FA), demonstrated a 2.5-fold increase in
tamoxifen and paclitaxel uptake [64]. Additionally, catio-
nic polymer micelles can be effectively mediated
through endosomal rupture or degradation (i.e., “proton
sponge” effect) but often failed at in vivo studies due to
rapid clearance from the circulation. Therefore, poly-
merosomes were developed which are cationic polymer
micelles that shield the positive charge with a neutral
polymer (such as PEG) coating. For example, polyelec-
trolyte complex (PEC) micelles with luteinizing hor-
mone-releasing hormone (LHRH) peptide exhibited
enhanced cellular uptake by increasing VEGF siRNA
gene silencing efficiency via receptor-mediated endocy-
tosis compared with those without LHRH on LHRH
receptor overexpressing ovarian cancer cells (A2780)
[65]. Epidermal growth factor (EGF)-conjugated
MePEG-b-PCL micelles can be delivered at a concentra-
tion 13 times more potent than free EGF [66].
pH Sensitive and Acid Cleavable Polymer Micelle
Nanoparticles
The main advantage of these micelles is that encapsu-
lated drugs are burst release in the acidic intracellular
compartments such as endosomes or lysosomes. These
formulations improved anti-tumor activity through intra-
cellular pH-sensitive drug delivery [67]. Additionally,
their folate conjugation was proven to enhance in vivo
anti-tumor efficacy at lower effective doses [68]. Further-
more, pH-sensitive micelles poly(L-hystidine)-b-PEG and
PLA-b-PEG-l-FOL (PHSM-f) were superior compared to
free and conventional polymer micelles [69]. The in vivo
experiments using a sensitive micelle system also demon-
strate accumulation of particles at the tumor site and
tumor regression was 4-5 fold greater than free DOX
after 27 days from the first i.v. injection. One study noted
that the half-life of DOX in the pH sensitive micelles
increased about 6-fold from free DOX in PBS and plasma
media. Their uptake at pH 6.8 was 5 times more than at
Figure 5 Uptake of nanoparticles by cancer cells. (A-B) Fluorescence images of A2780CP and MDA-MB-231 cells treated with PLGA NPs, FITC
in solution and FITC loaded PLGA NPs. Nuclei are stained blue with DAPI. (C-D) Fluorescence levels in A2780CP and MDA-MB-231 by Flow
Cytometer (Control cells, black line; nanoparticles in cells, blue line; FITC in cell, red line; and FITC-nanoparticles in cells, yellow lines).
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pH 7.4, indicating that the drug release triggered by the
reduced tumor pH was effective after the micelles were
accumulated by the EPR effect. Another novel tetra-
block copolymer [poly(ethylene glycol)-b-poly(L-histi-
dine)-b-poly(L-lactic acid)-b-poly(ethylene glycol)] is
capable of triggering release of DOX at pH 6.8 (i.e.,
tumor acidic pH) or pH 6.4 (i.e., endosomal pH) com-
pared to normal pH 7.4 [70]. This triggering or burst
release effect is dependent upon the molecular weight of
the PLA block existing in the tetra polymer which could
be a successful therapy for treating solid cancers or deli-
vering cytoplasmic cargo in vivo. A new formulation
composed of DOX in PDLLA-b-PEG-b-poly(L-histidine)-
TAT (transactivator of transcription) micelle was able to
expose TAT only at a slightly acidic tumor extracellular
pH to facilitate the internalization process [71]. These
micelles were tested with the xenograft models of human
ovarian tumor drug-resistant A2780/AD, human breast
tumor drug-sensitive MCF-7 and human lung tumor
A549 in a nude mice model, and all tumors considerably
regressed in size after three bolus injections at a dose of
10 mg DOX per kg body weight, at three day intervals,
while minimum weight loss was observed. The conjuga-
tion of drugs to the acid cleavable micelle polymers
facilitated prolonged release of drugs [72]. Doxorubicin-
conjugated PLLA-mPEG micelles were more potent
because they were taken up within cells with simulta-
neous rapid release of cleaved doxorubicin into the
cytoplasm from acidic endosomes [72]. A Triblock copo-
lymer conjugated with DOX through the end OH groups
of copolymers, indicated that hydrazone linkage was
cleaved under acidic conditions [73]. This behavior was
confirmed by flow cytometry and confocal microscopy
which demonstrated the extent of cellular uptake of
micelle conjugated DOX and distribution in the cyto-
plasm, endosomal/liposomal vesicles, and nucleus, while
the free drug was localized within the nucleus.
Cross-linked Polymer Micelle Nanoparticles
Various polymer micelle nanoparticles can control the
triggered release of the active therapeutic agents, but
most of these polymer micelle nanoparticles have draw-
backs as delivery carriers. For example, paclitaxel was
readily disassociated from the micelle nanoparticle just
after injection into the blood stream [74]. This dissocia-
tion may be due to the decomposition of micelles a- and
b-globulins and translocation of paclitaxel to the abun-
dant lipid components and carriers in blood [75]. To
address this drawback of polymer micelle nanoparticles, a
possible strategy is to design cross-linked biodegradable
micelles [76]. These micelles can shield drug molecules
tightly by the cross-linked corona and biodegradable
cross-linking releases the drug from micelles in a con-
trolled manner. Core micelle cross-linked with divalent
metal cations display high stability but also exhibit pH-
dependant swelling/collapse behavior [77]. These systems
have remarkably high platinum loading efficiency (i.e.,
~22% wt./wt.) and exhibited slow release of platinum in
a sustained manner from the cisplatin-loaded cross-
linked micelles in physiological saline. A new formulation




esters (NHS) prevented the dissolution of micelles due to
dilution effects and enabled pH sensitive and potentially
cleavable sites for micelle disassembly [78].
Novel Polymer Micelle Nanotechnology Strategies
Double-hydrophilic block copolymer based micelles have
more external hydrophilic behavior which mimics biolo-
gical fluid, unlike core-shell block copolymers [79,80].
The first hydrophilic charged block copolymer binds
to the chemotherapeutic agent and the second hydro-
philic block allows for steric stabilization. Polyamino
Figure 6 Multi-functional magnetic nanoformulation with curcumin/photo activator loaded, double layer, antibody conjugation for
various medical applications.
Yallapu et al. Journal of Ovarian Research 2010, 3:19
http://www.ovarianresearch.com/content/3/1/19
Page 7 of 10
acid-b-polyethylene oxide copolymers are excellent
examples which can bind the oppositely charged species
such as drugs (cisplatin and doxorubicin), proteins or
peptides, nucleic acids, and lysozymes [81-84]. Ultra-
sound sensitive polymer micelle nanoparticles are
another modality of drug targeting to tumors by a loca-
lized release. These micelles are degraded when sub-
jected to ultrasound into unimers which enhances the
cell membrane perturbation [85]. Even a short exposure
of 15 to 30 seconds to high-frequency ultrasound leads
to a significant increase in the intracellular DOX uptake
from pluronic micelles [86].
Magnetic nanoparticle based micelles act as drug car-
riers as well as external magnetic field guides in cancer
therapy treatments [87]. Developing micelle-magnetic
nanoparticles is a promising alternative. Recently, such
formulations were developed to gain different biological
functions while using only one formulation [88]. These
formulations can be applied not only for drug delivery
techniques but also magnetic resonance imaging (MRI),
visible targeting, magnetically targeted photodynamic
therapy, targeted thermo-sensitive chemotherapy, and
luminescence/near-infrared/multi-model imaging applica-
tions [89-96]. In this regard, one novel formulation
composed of an iron oxide nano-core stabilized with a
multi-layer coating could achieve better feasibility in drug
delivery, imaging and hyperthermia properties. However,
the higher hydrodynamic diameter (> 200 nm) in aqu-
eous medium limits its use in cancer therapeutic applica-
tions [97]. Therefore, we have been developing a novel
formulation of magnetic nanoparticles composed of
iron oxide core that is subsequently coated with
b-cyclodextrin (CD) and pluronic F127 polymer (F-127)
which possesses anti-cancer drug loading and antibody
conjugation features and can be utilized for multi-
functional applications (Figure 6). The advantages of this
formulation include smaller particle size, relatively lower
protein binding, higher drug loading efficiency and
enhanced particles uptake in cancer cells without ham-
pering inherent magnetization characteristics.
Conclusions
Polymer micelle nanotechnology has demonstrated that
nanoparticles are capable of loading anti-cancer drugs
which can be specifically targeted to tumors through the
conjugation of tumor specific antibody/moiety. Multi-
functional polymer micelles, including nanogels/mag-
netic based micelles, possess characteristics which could
improve ovarian cancer therapy. These formulations
have capabilities of MRI visible targeting, targeted
photodynamic therapy, thermosensitive therapy and
luminescence/near-infrared/multi-model imaging prop-
erties, which will allow tracking and monitoring of
nanoformulations and accumulated drug(s) at the tumor
site during the therapy procedure.
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